share_log

HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Lowers Price Target to $42

HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Lowers Price Target to $42

HC Wainwright & Co.维持Tarsus Pharmicals的买入,将目标股价下调至42美元
Benzinga ·  2023/08/11 06:26

HC Wainwright & Co. analyst Oren Livnat maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and lowers the price target from $50 to $42.

HC Wainwright&Co.分析师Oren Livnat维持塔尔苏斯制药公司(纳斯达克代码:TARS)的买入,并将目标价从50美元下调至42美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发